Differential neuroprotective effects of 5′-deoxy-5′- methylthioadenosine

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Moreno, Beatriz ^a   Lopez, Iciar ^b,c   Fernández Díez, Begoña ^a   Gottlieb, Miroslav ^d,e   Matute, Carlos ^d,e,f   Sánchez Gómez, María Victoria ^d   Domercq, María ^d   Giralt, Albert ^f,g   Alberch, Jordi ^f,g   Collon, Kevin W ^h   Zhang, Helen ^h   Parent, Jack M ^h   Teixido, Meritxell ⁱ   Giralt, Ernest ⁱ   Ceña, Valentín ^j   Posadas, Inmaculada ^j   Martínez Pinilla, Eva ^b   Villoslada, Pablo ^a   Franco, Rafael ^{b,c,d,e,f,g,h,i,j}  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e INSTITUTE OF CHEMISTRY   (Slovakia)

^f CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^j UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; ADENOSINE A2A RECEPTOR ANTAGONIST; MSX 3; N METHYL DEXTRO ASPARTIC ACID; PILOCARPINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN HYPOXIA; BRAIN ISCHEMIA; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; EPILEPTIC STATE; EXCITOTOXICITY; FETUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; RAT; SUBSTANTIA NIGRA; YOUNG ADULT;

ACUTE DISEASE; ADRENERGIC ANTAGONISTS; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CHRONIC DISEASE; DEOXYADENOSINES; DISEASE MODELS, ANIMAL; GLUCOSE; MALE; MICE; N-METHYLASPARTATE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXYGEN; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STATUS EPILEPTICUS; THIONUCLEOSIDES;

EID: 84897125902     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090671     Document Type: Article

References (29)

1. Williams-Ashman HG, Seidenfeld J, Galletti P (1982) Trends in the biochemical pharmacology of 59-deoxy-59 -methylthioadenosine. Biochem Pharmacol 31(3): 277-88. (Pubitemid 12222363)
2. Avila MA, García-Trevijano ER, Lu SC, Corrales FJ, Mato JM (2004) Methylthioadenosine. Int J Biochem Cell Biol 36(11): 2125-30. (Pubitemid 39094435)
3. Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodríguez- Ortigosa CM, Banales JM, et al. (2010) Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr22/2 Mice. PLoS ONE 5(12): e15690. doi:10.1371/journal.pone.0015690
4. Moreno B, Hevia H, Santamaria M, Sepulcre J, Muñoz J, et al. (2006) Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 60(3): 323-34. (Pubitemid 44520235)
5. Moreno B, Fernandez-Diez B, Di Penta A, Villoslada P (2010) Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Mult Scler 16(9): 1102-8.
6. Acheson A, Vogl W, Huttner WB, Thoenen H (1986) Methyltransferase inhibitors block NGF-regulated survival and protein phosphorylation in sympathetic neurons. The EMBO Journal 5 (11):2799-2803
7. Olson L, Bäckman L, Ebendal T, Eriksdotter-Jönhagen M, Hoffer B, et al. (1994) Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J Neurol 242(1 Suppl 1): S12-5. (Pubitemid 24367033)
8. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, et al. (1992) Cell death in the oligodendrocyte lineage. J Neurobiol 23:1221-1230.
9. Alberdi E, Sanchez-Gomez MV, Marino A, Matute C (2002) Ca(2+) influx through AMPA or kainate receptors alone is sufficient to initiate excitotoxicity in cultured oligodendrocytes. Neurobiol Dis 9:234-243. (Pubitemid 34261217)
10. Bruno V, Battaglia G, Copani A, Cespedes VM, Galindo MF, et al. (2001) An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur J Neurosci 13:1469-1478. (Pubitemid 32423335)
11. Vallejo-Illarramendi A, Torres-Ramos M, Melone M, Conti F, Matute C (2005) Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50:276-279. (Pubitemid 40769857)
12. Arbeloa J, Pérez-SamartÍn A, Gottlieb M, Matute C (2012) P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis 45(3):954-961
13. Longa EZ, Weinstein PR, Carlson S and Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91 (Pubitemid 19040218)
14. Pulsinelli WA, Brierley JB (1979) A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10: 267-272 (Pubitemid 9141527)
15. Kron MK, Zhang H, Parent JM (2010) The developmental stage of dentate granule cells dictates their contribution to seizure-induced plasticity. J Neurosci 30: 2051-2059
16. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-63.
17. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81:163-221.
18. Káradóttir R, Attwell D (2007) Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 145 (4):1426-1438. (Pubitemid 46602726)
19. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678-692
20. Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, et al. (2012) Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Prog Neurobiol 98(2): 222-38. doi: 10.1016/j.pneurobio.2012.06.005.
21. Panaro MA, Cianciulli A (2012) Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease. Curr Pharm Des 18(2): 200-8.
22. Greenwood J, Pryce G, Devine L, Male DK, dos Santos WL, et al. (1996) SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. Neuroimmunol 71 (1-2): 51-63. (Pubitemid 26413256)
23. Neumann H, Wekerle H (1998) Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J Neurophathol Exp Neurol 57: 1-9. (Pubitemid 28057171)
24. Stramentinoli G, Gennari F (1984) Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle. 20-33 (U.S. patent 4454122, 1984).
25. Di Penta A, Moreno B, Reix S, Fernández-Diez B, Villanueva M, et al. (2013) Oxidative stress and pro-inflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. Plos One 8(2): e54722.
26. Nozaki K, Beal MF (1992) Neuroprotective effects of L-kynurenine on hypoxiaischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab 12(3): 400-7.
27. Klein C, Patte-Mensah C, Taleb O, Bourguignon JJ, Schmitt M, et al. (2013) The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology 70C: 254-260.
28. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, et al. (2007) Characterization of the kynurenine pathway in human neurons. J Neurosci 27(47): 12884-92. (Pubitemid 350161746)
29. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, et al. (2001) 59-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 34(3): 386-94. (Pubitemid 32240817)